Your shopping cart is currently empty

Ulixertinib hydrochloride (Ulixertinib HCl) is an orally available, selective and potent ERK1/2 inhibitor with anticancer and antitumor activity that inhibits the NB cell cycle and promotes apoptosis, and may be used in the study of solid tumors.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $35 | In Stock | In Stock | |
| 5 mg | $56 | In Stock | In Stock | |
| 10 mg | $89 | In Stock | In Stock | |
| 25 mg | $143 | In Stock | In Stock | |
| 50 mg | $198 | In Stock | In Stock | |
| 100 mg | $372 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $62 | In Stock | In Stock |
| Description | Ulixertinib hydrochloride (Ulixertinib HCl) is an orally available, selective and potent ERK1/2 inhibitor with anticancer and antitumor activity that inhibits the NB cell cycle and promotes apoptosis, and may be used in the study of solid tumors. |
| In vitro | Combined treatment with Ulixertinib hydrochloride and VS-5584 for 48 hours significantly induced cell death in human pancreatic adenocarcinoma (HPAC) cells from the PDAC cell lines BxPC-3, MIAPaCa-2 and CFPAC. [1] |
| In vivo | Ulixertinib hydrochloride potently inhibited neuroblastoma tumor growth and prolonged the overall survival of the treated mice in two different neuroblastoma mice models. [2] |
| Molecular Weight | 469.79 |
| Formula | C21H23Cl3N4O2 |
| Cas No. | 1956366-10-1 |
| Smiles | ClC1=C(C=2C=C(C(N[C@H](CO)C3=CC(Cl)=CC=C3)=O)NC2)C=C(NC(C)C)N=C1.Cl |
| Relative Density. | no data available |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: < 0.1 mg/mL(insoluble) DMSO: 80 mg/mL (170.29 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.02 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.